Jazz Pharmaceuticals plc — Form 4
Filed August 31, 2026 · analyzed by the Insider Agent
4
▼ Likely negative
significance 59/100
What the filing says
EVP, Global Head of R&D & CMO Iannone Robert (JAZZ) sold 134K shares (~$19.2M) on the open market (67% of holdings). Large sale — ~67% of holdings.
Why this rating
Large sale — ~67% of holdings.
See more from August 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.